Vanderbilt-Ingram Cancer Center
Henry-Joyce Cancer Clinic
Nashville, TN
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Not yet accepting
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
Learn more- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
MagnetisMM-20
Phase 1B Study Evaluating Elranatamab in Combination with Carfilzomib/Dexamethasone or in Combination with PF-07901801 (maplirpacept) in Relapsed/Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- BCMA
- Phase 1
Accepting patients
ABBV-383
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- BCMA
- Phase 1
Accepting patients
BMF-219
A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)
Learn more- Menin Inhibitor
- Phase 1
Accepting patients
P-BCMA-ALLO1
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)
Learn more- CAR T Cell (Allogeneic)
- BCMA
- Phase 1
Accepting patients
ABBV-453
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
Learn more- BCL-2 Inhibitor
- Phase 1
Not yet accepting
COMMANDER
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (COMMANDER)
Learn more- CELMoD
- Monoclonal Antibody
- CD38
- Phase 1/2
2 hidden based on your filters. Show All